Photo of Professor Deenan Pillay

Professor Deenan Pillay

Director: Africa Centre for Population Health

Professor of Virology: University of KwaZulu Natal

Professor of Virology: University College London

Prof Deenan Pillay
P.O. Box 198
Mtubatuba 3935
South Africa

E: This email address is being protected from spambots. You need JavaScript enabled to view it.
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

T:+27 (0)35 5507509

2016

  1. Dimitrov, D. T., Boily, M.-C., Hallett, T. B., Albert, J., Boucher, C., Mellors, J. W., … van de Vijver, D. A. M. C. (2016). How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts’ Opinion and Its Influence on the Projected Public Health Impact. PloS One , 11 (7), e0158620. http://doi.org/10.1371/journal.pone.0158620
  2. Ferns, R. B., Tarr, A. W., Hue, S., Urbanowicz, R. A., McClure, C. P., Gilson, R., … Pillay, D. (2016a). Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals. Virology , 492 , 213–224. http://doi.org/10.1016/j.virol.2016.02.003
  3. Ferns, R. B., Tarr, A. W., Hue, S., Urbanowicz, R. A., McClure, C. P., Gilson, R., … Pillay, D. (2016b). Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronici ty in HIV-1 co-infected individuals. Virology , 492 , 213–224. http://doi.org/10.1016/j.virol.2016.02.003
  4. Hontelez, J. A. C., Tanser, F. C., Naidu, K. K., Pillay, D., & Bärnighausen, T. (2016). The Effect of Antiretroviral Treatment on Health Care Utilization in Rural South Africa: A Population-Based Cohort Study . PloS One , 11 (7), e0158015. http://doi.org/10.1371/journal.pone.0158015
  5. Manasa, J., Danaviah, S., Lessells, R. J., Elshareef, M., Tanser, F., Wilkinson, E., … de Oliveira, T. (2016). Increasing HIV-1 drug resistance between 2010 and 2012 in adults participating in population-based HIV surveillance in rural KwaZulu-Natal South Africa. AIDS Research and Human Retroviruses . http://doi.org/10.1089/AID.2015.0225
  6. Mulder, N. J., Christoffels, A., de Oliveira, T., Gamieldien, J., Hazelhurst, S., Joubert, F., … Tiffin, N. (2016). The Development of Computational Biology in South Africa: Successes Achieved and Lessons Learnt. PLOS Computational Biology , 12 (2), e1004395. http://doi.org/10.1371/journal.pcbi.1004395
  7. Oldenburg, C. E., Bärnighausen, T., Tanser, F., Iwuji, C. C., De Gruttola, V., Seage, G. R., … Harling, G. (2016). Antiretroviral therapy to prevent HIV acquisition in serodiscordant couples in a hyperendemic community in rural South Africa . Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America . http://doi.org/10.1093/cid/ciw335

2015

  1. Anekwe, T. D., Newell, M.-L., Tanser, F., Pillay, D., & Bärnighausen, T. (2015). The effect of childhood measles vaccination on educational attainment: A mother-fixed-effects study in rural South Africa. Vaccine. http://doi.org/10.1016/j.vaccine.2015.04.072
  2. Basson, A. E., Rhee, S.-Y., Parry, C. M., El-Khatib, Z., Charalambous, S., De Oliveira, T., … Morris, L. (2015). The impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy, 59(2), 960–971. http://doi.org/10.1128/AAC.04215-14
  3. Bor, J., Rosen, S., Chimbindi, N., Haber, N., Herbst, K., Mutevedzi, T., … Bärnighausen, T. (2015). Mass HIV Treatment and Sex Disparities in Life Expectancy: Demographic Surveillance in Rural South Africa. PLoS Medicine, 12(11). http://doi.org/10.1371/journal.pmed.1001905
  4. Chimbindi, N., Bor, J., Newell, M.-L., Tanser, F., Baltusen, R., Hontelez, J., … Bärnighausen, T. (2015). Time and money: the true costs of health care utilization for patients receiving “free” HIV/TB care and treatment in rural KwaZulu-Natal. JAIDS Journal of Acquired Immune Deficiency Syndromes, 1. http://doi.org/10.1097/QAI.0000000000000728
  5. Frost, S. D. W., & Pillay, D. (2015). Understanding drivers of phylogenetic clustering in molecular epidemiological studies of HIV. The Journal of Infectious Diseases, 211(6), 856–858. http://doi.org/10.1093/infdis/jiu563
  6. Haber, N., Pillay, D., Porter, K., & Bärnighausen, T. (2015). Constructing the cascade of HIV care: methods for measurement. Current Opinion in HIV and AIDS. Retrieved from http://europepmc.org/abstract/med/26545266
  7. Haber, N., Tanser, F., Herbst, K., PILLAY, D., & Barnighausen, T. (2015). Negative impact of South Africa’s disability grants on HIV/AIDS recovery. Journal of the International AIDS Society, 18.
  8. Hontelez, J. A. C., de Vlas, S., Tanser, F., Naidu, K., Pillay, D., Bärnighausen, T., & Baltussen, R. (2015). Effects of antiretroviral treatment on health care utilization in rural South Africa. Presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2015, Seattle. Retrieved from http://www.croiconference.org/sessions/effects-antiretroviral-treatment-health-care-utilization-rural-south-africa
  9. Huntington, S., Thorne, C., Newell, M.-L., Anderson, J., Taylor, G. P., Pillay, D., … Ireland National Study of HIV in Pregnancy Childhood (NSHPC). (2015). Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy. AIDS. http://doi.org/10.1097/QAD.0000000000000620
  10. Huntington, S., Thorne, C., Newell, M.-L., Anderson, J., Taylor, G. P., Pillay, D., … Sabin, C. (2015). The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy. AIDS, 29(17), 2269–2278. http://doi.org/10.1097/QAD.0000000000000826
  11. Kayondo, J., Ndembi, N., Parry, C. M., Cane, P. A., Hue, S., Goodall, R., … Mbisa, J. L. (2015). Intrapatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase Inhibitors. AIDS Research and Human Retroviruses. http://doi.org/10.1089/AID.2015.0035
  12. Klein, N., Palma, P., Luzuriaga, K., Pahwa, S., Nastouli, E., Gibb, D. M., … Rossi, P. (2015). Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission. The Lancet Infectious Diseases. http://doi.org/10.1016/S1473-3099(15)00052-3
  13. Lange, C. M., Hué, S., Violari, A., Cotton, M., Gibb, D., Babiker, A., … Gupta, R. K. (2015). Single genome analysis reveals linked, multi-class drug resistance in HIV-1 infected children from the Children with HIV Early Antiretroviral (CHER) study. JAIDS Journal of Acquired Immune Deficiency Syndromes, 1. http://doi.org/10.1097/QAI.0000000000000568
  14. Mbisa, J. L., Fearnhill, E., Dunn, D. T., Pillay, D., Asboe, D., Cane, P. A., & UK HIV Drug Resistance Database. (2015). Evidence of self-sustaining drug resistant HIV-1 lineages among untreated patients in the UK. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. http://doi.org/10.1093/cid/civ393
  15. Pillay, D., Herbeck, J., Cohen, M. S., Oliveira, T. de, Fraser, C., Ratmann, O., … PANGEA-HIV Consortium. (2015). PANGEA-HIV: phylogenetics for generalised epidemics in Africa. The Lancet. Infectious Diseases, 15(3), 259–261. http://doi.org/10.1016/S1473-3099(15)70036-8
  16. Smith, N. M. G., Mlcochova, P., Watters, S. A., Aasa-Chapman, M. M. I., Rabin, N., Moore, S., … Gupta, R. K. (2015). Proof-of-principle for immune control of global HIV-1 reactivation in vivo. Clinical Infectious Diseases, civ219. http://doi.org/10.1093/cid/civ219
  17. Sutherland, K. A., Goodall, R. L., McCormick, A., Kapaata, A., Lyagoba, F., Kaleebu, P., … Gupta, R. K. (2015). Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa. AIDS Research and Human Retroviruses. http://doi.org/10.1089/aid.2015.0138
  18. Sutherland, K. A., Parry, C. M., McCormick, A., Kapaata, A., Lyagoba, F., Kaleebu, P., … DART Virology Group. (2015). Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial. PLOS ONE, 10(9), e0137834. http://doi.org/10.1371/journal.pone.0137834
  19. Wensing, A. M., Calvez, V., Günthard, H. F., Johnson, V. A., Paredes, R., Pillay, D., … Richman, D. D. (2015). 2015 Update of the Drug Resistance Mutations in HIV-1. Topics in Antiviral Medicine, 23(4), 132–141.

2014

  1. Basson, A. E., Rhee, S.-Y., Parry, C. M., El-Khatib, Z., Charalambous, S., Oliveira, T. D., … Morris, L. (2014). The Impact of Drug Resistance Associated Amino Acid Changes on HIV-1 Subtype C on Susceptibility to Newer NNRTIs. Antimicrobial Agents and Chemotherapy, 59(2), 960–971. http://doi.org/10.1128/AAC.04215-14
  2. Cambiano, V., Bertagnolio, S., Jordan, M. R., Pillay, D., Perriëns, J. H., Venter, F., … Phillips, A. (2014). Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation. AIDS, 28 Suppl 1, S15–23. http://doi.org/10.1097/QAD.0000000000000082
  3. Dennis, A. M., Herbeck, J. T., Brown, A. L., Kellam, P., de Oliveira, T., Pillay, D., … Cohen, M. S. (2014). Phylogenetic studies of transmission dynamics in generalized HIV epidemics: An essential tool where the burden is greatest? JAIDS Journal of Acquired Immune Deficiency Syndromes. http://doi.org/10.1097/QAI.0000000000000271
  4. Gupta, R. K., Goodall, R. L., Ranopa, M., Kityo, C., Munderi, P., Lyagoba, F., … DART Virology Group and Trial Team. (2014). High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. Clinical Infectious Diseases, 58(7), 1023–1026. http://doi.org/10.1093/cid/cit933
  5. Hodcroft, E., Hadfield, J. D., Fearnhill, E., Phillips, A., Dunn, D., O’Shea, S., … UK CHIC Study. (2014). The contribution of viral genotype to plasma viral set-point in HIV infection. PLoS Pathogens, 10(5). http://doi.org/10.1371/journal.ppat.1004112
  6. Huntington, S., Thorne, C., Anderson, J., Newell, M.-L., Taylor, G., Pillay, D., … Sabin, C. (2014). Does pregnancy increase the risk of ART-induced hepatotoxicity among HIV-positive women? Journal of the International AIDS Society, 17(4(Suppl 3)). http://doi.org/10.7448/IAS.17.4.19486
  7. Huntington, S., Thorne, C., Anderson, J., Newell, M.-L., Taylor, G. P., Pillay, D., … National Study of HIV in Pregnancy and Childhood (NSHPC). (2014). Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women. BMC Infectious Diseases, 14. http://doi.org/10.1186/1471-2334-14-127
  8. Kityo, C., Gibb, D. M., Gilks, C. F., Goodall, R. L., Mambule, I., Kaleebu, P., … DART Trial Team. (2014). High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial. PLoS ONE, 9(3). http://doi.org/10.1371/journal.pone.0090772
  9. Low, A. J., Konate, I., Nagot, N., Weiss, H. A., Kania, D., Vickerman, P., … Yerelon Study Group. (2014). Cervicovaginal HIV-1 shedding in women taking antiretroviral therapy in Burkina Faso: a longitudinal study. Journal of Acquired Immune Deficiency Syndromes (1999), 65(2), 237–245. http://doi.org/10.1097/QAI.0000000000000049
  10. Raifman, J., Chetty, T., Tanser, F., Mutevedzi, T., Matthews, P., Herbst, K., … Bärnighausen, T. (2014). Preventing Unintended Pregnancy and HIV Transmission: Effects of the HIV Treatment Cascade on Contraceptive Use and Choice in Rural KwaZulu-Natal. JAIDS Journal of Acquired Immune Deficiency Syndromes, 67, S218–S227. http://doi.org/10.1097/QAI.0000000000000373
  11. Schultze, A., Paredes, R., Sabin, C., Phillips, A. N., Pillay, D., Kirk, O., … on behalf of EuroSIDA in EuroCOORD, UK CHIC and UK HDRD. (2014). Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure. Journal of the International AIDS Society, 17(4 (Suppl 3). http://doi.org/10.7448/IAS.17.4.19737
  12. Sutherland, K. A., Mbisa, J. L., Cane, P. A., Pillay, D., & Parry, C. M. (2014). Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1. The Journal of General Virology, 95(Pt 1), 190–200. http://doi.org/10.1099/vir.0.055624-0
  13. Wensing, A. M., Calvez, V., Günthard, H. F., Johnson, V. A., Paredes, R., Pillay, D., … Richman, D. D. (2014). 2014 Update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine, 22(3), 642–650

2013

  1. Bertagnolio, S., Perno, C. F., Vella, S., & Pillay, D. (2013). The Impact of HIV Drug Resistance on the Selection of First- and Second-Line ART in Resource-Limited Settings. The Journal of Infectious Diseases, 207 Suppl 2, S45–48. http://doi.org/10.1093/infdis/jit121
  2. Castro, H., Pillay, D., Cane, P., Asboe, D., Cambiano, V., Phillips, A., … UK Collaborative Group on HIV Drug Resistance. (2013). Persistence of HIV-1 transmitted drug resistance mutations. The Journal of Infectious Diseases, 208(9), 1459–1463. http://doi.org/10.1093/infdis/jit345
  3. Cotten, M., Lam, T. T., Watson, S. J., Palser, A. L., Petrova, V., Grant, P., … Nastouli, E. (2013). Full-Genome Deep Sequencing and Phylogenetic Analysis of Novel Human Betacoronavirus. Emerging Infectious Diseases, 19(5), 736–742. http://doi.org/10.3201/eid1905.130057
  4. Dolling, D. I., Dunn, D. T., Sutherland, K. A., Pillay, D., Mbisa, J. L., Parry, C. M., … Wakeman, K. (2013). Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. Journal of Antimicrobial Chemotherapy, 68(10), 2339–2343. http://doi.org/10.1093/jac/dkt199
  5. Huntington, S. E., Thorne, C., Bansi, L. K., Anderson, J., Newell, M.-L., Taylor, G. P., … UK Collaborative HIV Cohort (UK CHIC) Study and the National Study of HIV in Pregnancy and Childhood (NSHPC). (2013). Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care. AIDS (London, England), 27(1), 95–103. http://doi.org/10.1097/QAD.0b013e3283565df1
  6. Klein, N., Sefe, D., Mosconi, I., Zanchetta, M., Castro, H., Jacobsen, M., … Paediatric European Network for Treatment of AIDS 11 Trial Team. (2013). The immunological and virological consequences of planned treatment interruptions in children with HIV infection. PLoS ONE, 8(10). http://doi.org/10.1371/journal.pone.0076582
  7. Price, H., Dunn, D., Pillay, D., Bani-Sadr, F., de Vries-Sluijs, T., Jain, M. K., … Gilson, R. (2013). Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS ONE, 8(7). http://doi.org/10.1371/journal.pone.0068152
  8. Titanji, B. K., Aasa-Chapman, M., Pillay, D., & Jolly, C. (2013). Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells. Retrovirology, 10(1). http://doi.org/10.1186/1742-4690-10-161
  9. Touloumi, G., Pantazis, N., Pillay, D., Paraskevis, D., Chaix, M.-L., Bucher, H. C., … CASCADE collaboration in EuroCoord. (2013). Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 56(6), 888–897. http://doi.org/10.1093/cid/cis1000
  10. Yebra, G., Holguín, A., Pillay, D., & Hué, S. (2013). Phylogenetic and demographic characterization of HIV-1 transmission in Madrid, Spain. Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases, 14, 232–239. http://doi.org/10.1016/j.meegid.2012.12.006

2012

  1. Dennis, A. M., Hué, S., Hurt, C. B., Napravnik, S., Sebastian, J., Pillay, D., & Eron, J. J. (2012). Phylogenetic insights into regional HIV transmission. AIDS (London, England), 26(14), 1813–1822. http://doi.org/10.1097/QAD.0b013e3283573244
  2. Gall, A., Ferns, B., Morris, C., Watson, S., Cotten, M., Robinson, M. … Kellam, P. (2012). Universal Amplification, Next-Generation Sequencing, and Assembly of HIV-1 Genomes. Journal of Clinical Microbiology, 50(12), 3838–3844. http://doi.org/10.1128/JCM.01516-12
  3. Gupta, R. K., Jordan, M. R., Sultan, B. J., Hill, A., Davis, D. H., Gregson, J., … Bertagnolio, S. (2012). Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet, 380(9849), 1250–1258. http://doi.org/10.1016/S0140-6736(12)61038-1
  4. Huntington, S. E., Bansi, L. K., Thorne, C., Anderson, J., Newell, M.-L., Taylor, G. P., … Sabin, C. A. (2012). Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women. BMC Medical Research Methodology, 12, 110. http://doi.org/10.1186/1471-2288-12-110
  5. Mbisa, J. L., Hué, S., Buckton, A. J., Myers, R. E., Duiculescu, D., Ene, L., … Pillay, D. (2012). Phylodynamic and Phylogeographic Patterns of the HIV Type 1 Subtype F1 Parenteral Epidemic in Romania. AIDS Research and Human Retroviruses, 28(9), 961–966. http://doi.org/10.1089/aid.2011.0390
  6. Price, H., Bansi, L., Sabin, C. A., Bhagani, S., Burroughs, A., Chadwick, D., … Gilson, R. (2012). Hepatitis B Virus Infection in HIV-Positive Individuals in the UK Collaborative HIV Cohort (UK CHIC) Study. PLoS ONE, 7(11). http://doi.org/10.1371/journal.pone.0049314
  7. Tong, C. Y. W., Cane, P. A., & Pillay, D. (2012). ARHAI: antiviral resistance. The Journal of Antimicrobial Chemotherapy, 67 Suppl 1, i65–68. http://doi.org/10.1093/jac/dks197
  8. Von Wyl, V., Cambiano, V., Jordan, M. R., Bertagnolio, S., Miners, A., Pillay, D., … Phillips, A. N. (2012). Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring. PLoS ONE, 7(8). http://doi.org/10.1371/journal.pone.0042834

2015

  1. Huntington, S., Thorne, C., Newell, M.-L., Anderson, J., Taylor, G. P., Pillay, D. … Ireland National Study of HIV in Pregnancy Childhood (NSHPC). (2015). Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy. AIDS. http://doi.org/10.1097/QAD.0000000000000620
  2. Smith, N. M. G., Mlcochova, P., Watters, S. A., Aasa-Chapman, M. M. I., Rabin, N., Moore, S., … Gupta, R. K. (2015). (joint senior author) Proof-of-principle for immune control of global HIV-1 reactivation in vivo. Clinical Infectious Diseases, civ219. http://doi.org/10.1093/cid/civ219

2014

  1. Basson, A. E., Rhee, S.-Y., Parry, C. M., El-Khatib, Z., Charalambous, S., Oliveira, T. D., … Morris, L. (2014). The Impact of Drug Resistance Associated Amino Acid Changes on HIV-1 Subtype C on Susceptibility to Newer NNRTIs. Antimicrobial Agents and Chemotherapy, 59(2), 960–971. http://doi.org/10.1128/AAC.04215-14
  2. Cambiano, V., Bertagnolio, S., Jordan, M. R., Pillay, D., Perriëns, J. H., Venter, F., … Phillips, A. (2014). Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation. AIDS, 28 Suppl 1, S15–23. http://doi.org/10.1097/QAD.0000000000000082
  3. Sutherland, K. A., Mbisa, J. L., Cane, P. A., Pillay, D., & Parry, C. M. (2014). Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1. The Journal of General Virology, 95(Pt 1), 190–200. http://doi.org/10.1099/vir.0.055624-0
  4. Wensing, A. M., Calvez, V., Günthard, H. F., Johnson, V. A., Paredes, R., Pillay, D., … Richman, D. D. (2014). 2014 Update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine, 22(3), 642–650

2013

  1. Bertagnolio, S., Perno, C. F., Vella, S., & Pillay, D. (2013). The Impact of HIV Drug Resistance on the Selection of First- and Second-Line ART in Resource-Limited Settings. The Journal of Infectious Diseases, 207 Suppl 2, S45–48. http://doi.org/10.1093/infdis/jit121
  2. Castro, H., Pillay, D., Cane, P., Asboe, D., Cambiano, V., Phillips, A., … UK Collaborative Group on HIV Drug Resistance. (2013). Persistence of HIV-1 transmitted drug resistance mutations. The Journal of Infectious Diseases, 208(9), 1459–1463. http://doi.org/10.1093/infdis/jit345
  3. Cotten, M., Lam, T. T., Watson, S. J., Palser, A. L., Petrova, V., Grant, P., … Nastouli, E. (2013). Full-Genome Deep Sequencing and Phylogenetic Analysis of Novel Human Betacoronavirus. Emerging Infectious Diseases, 19(5), 736–742. http://doi.org/10.3201/eid1905.130057

HIV antivirals and drug resistance

Deenan is an academic clinical virologist with a research and clinical interest in HIV transmission, antiviral therapy and drug resistance. He was he previously Head of the Division of Infection and Immunity and Professor of Virology at University College London (UCL). He was appointed by the Wellcome Trust as the Director of the Africa Centre for Population Health Studies in 2013. He is seconded from UCL, where he remains Professor of Virology, and is also Professor of Virology at the University of KwaZulu Natal. He has held a number of senior scientific roles, including as Director of the UCL Biomedical Research Centre.

His research work focuses on HIV virus evolution, in particular how HIV escapes drug selective pressure.  It spans wet (genomic, phenotypic) and dry (bioinformatics) laboratory approaches, as well as linking in vitro data to national and international population estimates.  Deenan led the virology work in the pivotal MRC-funded DART trial of antiretroviral therapy in Africa to estimate the impact of drug resistance on the efficacy of treatment rollout in endemic areas, feeding into WHO guidelines.  He is PI on the BMGF Pangea_HIV consortium which maps HIV transmission dynamics in the African generalised epidemcis, through full length viral sequencing. He is also PI on the ANRS Treatment as Prevention Trial, based at the Africa Centre for Population Health.